Medyria secures CHF 1.5M to advance PyCath development and expand globally
scroll south
Swiss medtech startup Medyria AG has raised CHF 1.5 million in a funding round led by Lisbon-based VC firm Buenavista. The investment will support the continued development of the company’s PyCath system and strengthen its international presence.
The CHF 1.5 million round, led by Buenavista and its managing partner Bibi Sattar Marques, will allow Medyria to move forward with key milestones for its PyCath catheter system. The funding will support the first-in-human clinical study and preparation of a 510(k) submission to the U.S. Food and Drug Administration (FDA), both critical steps toward market access in the United States.In parallel, Medyria has established Medyria Atlantic1 in Portugal. The new affiliate will coordinate clinical affairs, oversee commercial development in Europe, and manage part of the PyCath system’s production and R&D efforts. This move reflects Medyria’s strategy to expand its operational capabilities and strengthen its footprint across Europe and the U.S.
The investment round marks an important phase in Medyria’s growth as it progresses toward the commercialization of PyCath and scales its impact in the medical device sector.
Medyria won Venture Kick in 2012 and was named a TOP 100 Swiss Startup in 2016. In 2019, the startup was chosen to participate in the Venture Leaders Life Science program, which took ten entrepreneurs on an investor roadshow in Boston, a hub of the Medtech and Biotech sectors, as well as the Startup Champions Seed Night event in Lausanne.
Medyria AG: Advanced and intuitive methods for the visualization and con
Medyria has developed a unique technology for the direct measurement of the Blood Flow Velocity (BFV) and is developing medical devices that integrates the BFV sensor. Recently we started the develop... Read more
